<DOC>
	<DOCNO>NCT00472004</DOCNO>
	<brief_summary>This Phase IV prospective , randomize , open label , comparative , multicenter study generally healthy postmenopausal woman receive Totelle ( 17B Estradiol/TMG CC ( 1mg ) ) Livial ( Tibolone ) .</brief_summary>
	<brief_title>Study Comparing 17B Estradiol/TMG CC 1mg Vs. Tibolone In Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Tibolone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Generally healthy postmenopausal woman Last natural ( without exogenous hormone therapy ) menstrual cycle complete least 12 consecutive month prior screen without kind gynecological bleeding period At least 1 year natural occur amenorrhea Known suspect estrogendependent neoplasia Endometrial hyperplasia Any malignancy exception history basal cell carcinoma skin</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>